AIDSWEEKLY Plus; Monday, December 17, 2007
Staff Medical Writers

"This appears to be the most promising strategy to date for a safe, effective method of reducing excess visceral fat deposits and improving lipid abnormalities in HIV-infected patients, thereby improving their risk for cardiovascular disease," says Steven Grinspoon, MD, of the MGH Neuroendocrine Unit and Program in Nutritional Metabolism, the report's senior and corresponding author.

A significant number of HIV-infected individuals who receive antiviral therapy develop lipodystrophy. Symptoms of the syndrome include a loss of subcutaneous fat in the face, arms, and legs and increased fat deposits in the abdomen. The metabolic aspects of the syndrome – changes in cholesterol and other blood lipids, and development of insulin resistance – could increase the risk of cardiovascular disease in HIV-infected patients.

Earlier studies found that growth hormone secretion is reduced in men with lipodystrophy. Since directly injecting growth hormone can have significant side effects, researchers at the MGH previously investigated the use of growth-hormone-releasing hormone (GHRH) to increase levels in a way that mimics natural control of hormone levels. In a 2004 study, they showed that patients receiving GHRH injections appeared to have more normal growth hormone levels and improvements in fat distribution.

The current study followed up an earlier Phase 2 study of tesamorelin, a growth-hormone-releasing factor that can be dosed only once a day instead of twice. Study participants – HIV lipodystrophy patients recruited from 43 sites around the U.S. and Canada – were randomly assigned to receive either tesamorelin or a placebo, self administered daily for six months. At the end of the study period, researchers measured participants’ visceral fat – deposits around organs deep in the abdomen – and subcutaneous fat in arms and legs. They also recorded key lipid measurements and levels of the hormone IGF-1, which reflects the release of growth hormone. In addition, participants were surveyed at the beginning and end of the study on their perceptions of their bodies and any distress they felt.

Among the more than 325 participants who completed the study, those receiving tesamorelin had significant reductions in abdominal fat, measured by CT scan, resulting in a 20 percent difference from those in the placebo group. Lipid measurements – including triglycerides, total cholesterol, HDL, and the ratio of total cholesterol to HDL – also improved significantly; IGF-1 levels reflected increased release of growth hormone in the tesamorelin group. Participants receiving the drug also reported significant improvements in their body image and reduced levels of distress.

"Longer-term studies are necessary to confirm our results, and another confirmatory Phase 3 trial needs to be completed to comply with FDA requirements," says Grinspoon. "But this study shows clearly that the novel strategy of inducing the release of endogenous growth hormone can improve symptoms of lipodystrophy, relieving patient distress – which may improve their compliance with therapy – and reducing several cardiovascular risk factors." Grinspoon is an associate professor of Medicine at Harvard Medical School.

Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Cardiology, Cardiovascular Disease, Drug Resistance, Endocrinology, Gastroenterology, HIV, Hormones, Human Immunodeficiency Virus, Lipodystrophy, Therapy, Treatment, Virology, Massachusetts General Hospital.

This article was prepared by AIDS Weekly editors from staff and other reports.

2007-12-17
AW071207

Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.